Literature DB >> 8888381

Hypnotic self administration and dose escalation.

T Roehrs1, B Pedrosi, L Rosenthal, T Roth.   

Abstract

The dependence liability of benzodiazepines in the context of their use as hypnotics (i.e. by insomnia patients as pre-sleep medications) is unresolved. A recent study found that insomniacs self administer capsules at bedtime at a high rate, with triazolam (0.25 mg) taken as often as placebo. This study sought to determine if differential self administration would develop when multiple capsules are available nightly. Eighteen men and women, age 21-45 years, with insomnia complaints (nine with objective sleep disturbance and nine without) were studied, 1 week with placebo and 1 week with triazolam (0.25 mg). The two conditions were administered double-blind and presented in a counter-balanced order with a week between conditions. In each condition, after 3 consecutive sampling nights of the available single capsule for that condition, subjects could self administer 0-3 capsules before bed on the 4 subsequent nights. Triazolam was self administered as many nights as placebo, but the number of placebo capsules self administered was twice that of triazolam capsules. The objective insomniacs self administered more capsules than the subjective insomniacs and neither group differentially choose triazolam over placebo. The number of triazolam capsules taken nightly was stable and the number of placebo capsules variable. It is concluded that insomniacs show no short-term escalation of triazolam dose, but do choose an increased and variable number of placebos, a pattern which is interpreted as being insomnia relief-seeking behavior.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888381     DOI: 10.1007/bf02805988

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

Review 2.  Testing the abuse liability of anxiolytic and hypnotic drugs in humans.

Authors:  H de Wit; R R Griffiths
Journal:  Drug Alcohol Depend       Date:  1991-06       Impact factor: 4.492

3.  Consensus conference. Drugs and insomnia. The use of medications to promote sleep.

Authors: 
Journal:  JAMA       Date:  1984-05-11       Impact factor: 56.272

4.  Rebound insomnia and hypnotic self administration.

Authors:  T Roehrs; L Merlotti; F Zorick; T Roth
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Efficacy of a reduced triazolam dose in elderly insomniacs.

Authors:  T Roehrs; F Zorick; R Wittig; T Roth
Journal:  Neurobiol Aging       Date:  1985       Impact factor: 4.673

6.  Pharmacology and hypnotic efficacy of triazolam.

Authors:  T Roth; T A Roehrs; F J Zorick
Journal:  Pharmacotherapy       Date:  1983 May-Jun       Impact factor: 4.705

7.  Insomnia and its treatment. Prevalence and correlates.

Authors:  G D Mellinger; M B Balter; E H Uhlenhuth
Journal:  Arch Gen Psychiatry       Date:  1985-03

8.  Lack of preference for diazepam in anxious volunteers.

Authors:  H de Wit; E H Uhlenhuth; D Hedeker; S G McCracken; C E Johanson
Journal:  Arch Gen Psychiatry       Date:  1986-06
  8 in total
  8 in total

Review 1.  Hypnotics: an update.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; Surilla Randall; Erica Harris; Renee Maan; Thomas Roth
Journal:  Sleep       Date:  2011-02-01       Impact factor: 5.849

Review 3.  Insomnia pharmacotherapy.

Authors:  Timothy Roehrs; Thomas Roth
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

4.  Consensus on drug treatment, definition and diagnosis for insomnia.

Authors:  E Estivill; A Bové; D García-Borreguero; J Gibert; J Paniagua; G Pin; F J Puertas; R Cilveti
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

5.  Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep.

Authors:  Thomas Roth; Gary K Zammit; Martin B Scharf; Robert Farber
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

Review 6.  Sleep and alertness disturbance and substance use disorders: A bi-directional relation.

Authors:  Timothy Roehrs; Mohammad Sibai; Thomas Roth
Journal:  Pharmacol Biochem Behav       Date:  2021-02-12       Impact factor: 3.533

7.  Factors associated with long-term use of hypnotics among patients with chronic insomnia.

Authors:  Yoshikazu Takaesu; Yoko Komada; Shoichi Asaoka; Tatsuo Kagimura; Yuichi Inoue
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 8.  Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics.

Authors:  Yumi Aoki; Yoshikazu Takaesu; Masahiro Suzuki; Isa Okajima; Masahiro Takeshima; Akiyoshi Shimura; Tomohiro Utsumi; Nozomu Kotorii; Hidehisa Yamashita; Kenichi Kuriyama; Norio Watanabe; Kazuo Mishima
Journal:  Neuropsychopharmacol Rep       Date:  2021-11-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.